Balaji Amines doubles profit, commissions India's first DME plant

Tipsheet Editorial — Mon, 27 Jul 2026 19:30:23 GMT

Q1 net profit more than doubled to ₹78 cr as revenue rose 26% to ₹461 cr. The company also flagged completion of a 100,000 tpa dimethyl ether plant, a first for India.

What’s new

Revenue up 26% YoY to ₹461 crore; EBITDA margin expanded to 26% from 17%.
India's first commercial-scale dimethyl ether plant commissioned at 100,000 tpa.
N-methyl morpholine and acetonitrile expansions on track for FY27.

Why it matters

The earnings beat confirms Balaji Amines is riding a strong demand cycle in specialty chemicals. The DME plant opens a new revenue stream in an import-substitution market, and the subsidiary's ₹750 crore capex pipeline suggests management is betting the cycle has legs.

What we’re watching

Volume growth trajectory – 21,587 tonnes this quarter vs prior year.
DME plant utilization and margin contribution over FY27.
Balaji Speciality Chemicals capex milestones as brownfield/greenfield units come online.

The full read

A clean beat. Revenue hit ₹461 crore, up 26%; EBITDA more than doubled to ₹121 crore, pushing the margin from 17% to 26%. Net profit came in at ₹78 crore, more than double last year's ₹31 crore. The star move is the commissioning of India's first commercial-scale dimethyl ether plant at 100,000 tpa, adding a new product vertical in a market currently reliant on imports. The subsidiary's ₹750 crore capex plan is also tracking toward FY27 milestones, with both brownfield and greenfield units on schedule, pointing to sustained growth beyond the current quarter. The quarterly print confirms a healthy operating trajectory; the DME plant gives the narrative something more than just a cyclical upswing.

Primary source: BSE · NSE

Balaji Amines net profit surges 97% in Q1 FY27

Tipsheet Editorial — Mon, 27 Jul 2026 18:28:11 GMT

Revenue climbs 27% to ₹455.9 cr as improved margins in core amines drive a decisive quarter for the specialty chemicals maker.

What’s new

Consolidated revenue up 27% to ₹455.9 crore in Q1 FY27.
Net profit attributable to shareholders surged 97% to ₹74.9 crore.
Standalone PBT nearly doubled to ₹97.8 crore.

Why it matters

The 97% profit leap on a 27% revenue gain shows improved margins in Balaji's core amines business. With negligible debt (D/E 0.07) and a freshly commissioned DME plant, the earnings beat adds conviction to a turnaround story investors have been tracking.

What we’re watching

Management commentary on demand sustainability post-agriculture season.
DME plant utilisation ramp-up and margin contribution.
Any guidance revision after the earnings call.

The full read

Balaji Amines delivered a quarter that turns the narrative. Revenue of ₹455.9 crore (up 27%) is solid, but net profit of ₹74.9 crore (up 97%) is the headline. The company runs with near-zero debt (D/E 0.07) and a fresh DME plant online, so improved margins flow straight to the bottom line. Standalone PBT nearly doubled to ₹97.8 crore. This isn't a one-off blip: it confirms a recovery six months in the making. Investors who held through the trough now get the payoff. The earnings call next will test whether management sees this as a sustainable run rate or a seasonal high.

Primary source: BSE · NSE

Balaji Amines Ltd. (BALAMINES) — Tipsheet

Balaji Amines doubles profit, commissions India's first DME plant

What’s new

Why it matters

What we’re watching

The full read

Balaji Amines net profit surges 97% in Q1 FY27

What’s new

Why it matters

What we’re watching

The full read